Michael Pishvaian, MD
Enriched profileAssociate Professor of Oncology; Director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, Johns Hopkins Kimmel Cancer Center (Washington DC / National Capital Region) · Johns Hopkins University
Michael Pishvaian is Associate Professor of Oncology; Director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, Johns Hopkins Kimmel Cancer Center (Washington DC / National Capital Region) at Johns Hopkins University. OpenAlex indexes 544 publications with 9,809 citations (h-index 49); ClinicalTrials.gov lists 18 registered studies with this person as an investigator.
Data verified 15 Oct 2026
Overview
Updated 16 Oct 2026
Michael Pishvaian, MD, is Associate Professor of Oncology at Johns Hopkins University / Johns Hopkins Kimmel Cancer Center (Sibley Memorial Hospital, Washington DC National Capital Region). The public record shows 544 publications with 9,809 citations (h-index 49), centered on Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 23 companies, 1 NIH-funded awards (2019–2022).
- Most recent indexed publication: 2026 · Nature communications
- Top research focus: Pancreatic and Hepatic Oncology Research
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 131.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- The Canopy Cancer Collective Clinical Registry Protocol
Sponsor: Canopy Cancer Collective, LLC
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 16 Oct 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year202523 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- Partner Therapeutics, Inc.Program year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44.3%Serotonin-3 Receptor Antagonist19.2%Ondansetron Hcl100%Part D≥53 patientsAntidiarrheal microorganisms10.7%Creon100%Part D≥18 patients+ 3 more classes in this area
Nervous system
32.5%Phenothiazine17.8%Prochlorperazine Maleate100%Part D≥52 patientsOpioid Agonist12.1%Oxycodone Hcl61%Tramadol Hcl39%Part D<11 patients+ 1 more class in this area
Sensory organs
10.9%Corticosteroid10.9%Dexamethasone100%Part D≥36 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2019–2022 per NIH RePORTER. The latest:
Congress activity
Updated 16 Oct 2026
165 congress contributions (2006–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Effect of surgeon specialty and health system characteristics on outcomes after pancreatic adenocarcinoma resection.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.
Nature communications
Article2026 - PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Journal of clinical oncology
Clinical Trial2025 - Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/michael-pishvaian-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
profiles.hopkinsmedicine.org/provider/mike-j-pishvaian/2705697
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Other
pure.johnshopkins.edu/en/persons/mike-pishvaian
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pure.johnshopkins.edu ↗ - ResearchGate
researchgate.net/scientific-contributions/Michael-J-Pishvaian-56095935
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/mpishvaian
- LinkedIn
linkedin.com/in/michael-pishvaian-5592b458
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/tumorboardtues
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - Doximity
Doximity profile: Dr. Michael Pishvaian, MD, Oncology, Washington, DC
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - LinkedIn
LinkedIn: Michael Pishvaian, The Johns Hopkins University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Vice Chair
Scientific and Medical Advisory Board, Pancreatic Cancer Action Network (PanCAN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pancan.org ↗ - Alliance Co-Chair
Pancreatic Cancer Subcommittee; Alliance member, NIH Pancreatic Cancer Task Force
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
Secondary affiliations
appointments beyond the home institution- Prior role: Co-Director for Clinical Research
Zayed Center for Pancreatic Cancer Research, MD Anderson Cancer Center
2019provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytoday.captivate.fm ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- The Pancreatic Cancer Podcast
guest, precision medicine discussion with Drs. Winter and Brody
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - Research To Practice Oncology Video Podcast: Pancreatic Cancer
interview series
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →videopodcast.researchtopractice.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Tanguy Seiwert, MD
Johns Hopkins University
Evan Lipson, MD
Johns Hopkins University
Pradeep Ramulu, MD
Johns Hopkins University
Nicholas Maragakis, MD
Johns Hopkins University
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH